Marvin Slepian, MD, compares the hemocompatibility of Impella 5.5 to Centrimag discussing hemolysis, platelet activation, microparticle generation, and vWF alteration.
William O'Neill, MD, shares insights from the National Cardiogenic Shock Initiative (NCSI) Study that are driving improved outcomes in patients with AMI cardiogenic shock.
Duane Pinto, MD, MPH, discusses the new single access technique, designed to avoid an additional arterial access, and reduce associated complications as well as make the procedure more rapid.
Learn when and how to use echocardiography to visualize in real-time the relationship of the Impella 5.5 with SmartAssist to structures within the left ventricle.
Ameloot et al. report significant reduction in myocardial injury with target MAP between 80/85 and 100 mmHg in post-cardiac arrest patients with shock after AMI.
This FAQ discusses the PROTECT series of FDA clinical studies, which include the PROTECT I study, the PROTECT II randomized controlled trial, and the PROTECT III study.
NPS-1674
This information is intended for use by customers, patients, and healthcare professionals in [region] only. We recognize that the Internet is a global communications medium; however, laws, regulatory requirements, and product information for medical products can vary from country to country. The product information included here may not be appropriate for use outside [region], and the information from other sites you visit may not be appropriate for use in [region].
The Protected PCI community
is now on HeartRecovery.com
Providing education and training to help health care professionals
recover hearts, oxygenate the body and save lives.
